Global Recombinant Protein Market will Reach Nearly US$ 460 Mn by 2022-end
Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=186
A new report published by Fact.MR estimates the global recombinant protein market to witness expansion at a moderate CAGR during the forecast period 2017 to 2022. Revenues from the global recombinant protein market will reach nearly US$ 460 Mn by 2022-end.
Through genetic engineering, and cell engineering, recombinant protein are produced from creature body. The recombinant protein technology now stands at the edge of biotechnology production. Becoming the new standard, this technology is witnessing a gradual shift from bulk production procedure towards post-production techniques, which in turn promises an enhanced delivery and stability. The highly effective recombinant proteins play an integral part in treating specific diseases, such as hemophilia. However, blood coagulation factor is excluded, as it possesses an extremely limited source. A large number of recombinant protein drugs utilized are human proteins. This is mainly to compensate functional proteins in vivo defects, and for increasing the functions of proteins in a body. These factors provide recombinant proteins with substantially higher safety as compared to small molecules, further leading towards higher approval rates.
The clinical trial periods for recombinant proteins are comparatively shorter than small molecule drugs, which further aids in enhancing patient protection, and renders pharmaceutical companies with a relatively longer exclusive sales time. Factors such as these are driving the development, and demand for recombinant proteins. Recombinant proteins target diseases such as cardiovascular diseases, endocrine diseases, viral diseases, and cancer. In addition, the global recombinant protein market has a larger extension space, with few approval drugs available without any alternative products in therapeutic areas. These factors might influence growth of the market over the forecast period. However, factors such as technical barriers, financial barriers have made recombinant protein technology expensive. Moreover, replication of recombinant proteins incurs many challenges, as compared to replication of small molecule chemicals. These factors may impede growth of the market in the near future.
North America to Remain Dominant in the Market
North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.
Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.
Although academic & research institutes are expected to remain the largest end-users of recombinant proteins in terms of revenues, sales in biopharmaceutical companies will register the highest CAGR compared to all the other end-user segments through 2022. Revenues from sales of recombinant proteins in academic & research institutes will account for over one-third market share during 2017 to 2022.
Leading players in the global recombinant protein market include Abcam plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., BPS Bioscience Inc., PerkinElmer, Inc., Crown Bioscience, Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich, and Thermo Fisher Scientific, Inc.
Browse Full Report with TOC- https://www.factmr.com/report/186/recombinant-protein-market
Table of Content:
1. Global Recombinant Proteins Market - Executive Summary
2. Global Recombinant Proteins Market Overview
2.1.1. Global Recombinant Proteins Market Taxonomy
2.1.2. Global Recombinant Proteins Market Definition
2.2. Global Recombinant Proteins Market Size (US$ Mn) and Forecast, 2012-2022
2.2.1. Global Recombinant Proteins Market Y-o-Y Growth
2.3. Global Recombinant Proteins Market Dynamics
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis
2.8. List of Distributors
2.9. Key Participants Market Presence (Intensity Map) By Region
3. Global Recombinant Proteins Market Analysis and Forecast By Product Type
3.1. Global Recombinant Proteins Market Size and Forecast By Product Type, 2012-2022
3.1.1. Immune Checkpoint Regulators Recombinant Proteins Market Size and Forecast, 2012-2022
18.104.22.168. Revenue (US$ Mn) Comparison, By Region
22.214.171.124. Market Share Comparison, By Region
126.96.36.199. Y-o-Y growth Comparison, By Region
3.1.2. Chemokines Recombinant Proteins Market Size and Forecast, 2012-2022
188.8.131.52. Revenue (US$ Mn) Comparison, By Region
184.108.40.206. Market Share Comparison, By Region
220.127.116.11. Y-o-Y growth Comparison, By Region
Check Discount on This Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=186
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
27 Upper Pembroke Street,
Dublin 2, Ireland
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Recombinant Protein Market will Reach Nearly US$ 460 Mn by 2022-end here
News-ID: 1008259 • Views: 143
More Releases from Fact.MR
PCR and Real-time PCR Molecular Diagnostics Market to Surpass US$ 6 Bn by 2030, …
As per data from the World Health Organization, millions of deaths can be attributed to diseases such as cancer and HIV each year. Further, the recent outbreak of the COVID-19 virus has also created massive demand for effective diagnostics processes. The PCR and real-time PCR molecular diagnostics market has been gaining traction in recent years on the back of investments by PCR diagnostic test manufacturers towards the incorporation of molecular
Biobanking Market to Soar to US$ 3.5 Bn by 2027, Notes Fact.MR
Biobanks are a type of repository which is used in the storage of biological samples, including human and animal tissues, which primarily find use in research applications. Consequently, the process of biobanking has become a very important part of medical research and has played a major role in modern science fields such as personalized medications, and genomics. The global biobanking market is expected to grow at a healthy CAGR of ~
Mini LED Market to Expand 7.5X by 2030, Finds New Study by Fact.MR
In recent years, increasing popularity of OLED TVs in China and India has been significantly influencing growth of the mini LED market. With an increase in disposable income of a majority of the population in these countries, the inclination towards smart screens with higher lifespan and better performance is expected to open up numerous growth opportunities for the mini LED market. Moreover, aspiring and affluent households have increased their spending
Uncertainty Surrounding COVID-19 to Shave-off Growth in Electrical Steel Market …
The global electrical steel market has utilized the opportunities in the market over the last decade with sales of electrical steel pegged at US$ 20.4 Bn in 2019. However, sales are set to plummet during in the middle two quarters of 2020 owing to COVID-19. In addition, several automakers have shuttered their production units, causing incalculable loss to the electrical steel market in 2020. However, the demand of electrical steel
More Releases for Recombinant
Global Recombinant Factor VIII Market Research Report
This report studies the global Recombinant Factor VIII market status and forecast, categorizes the global Recombinant Factor VIII market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Shire (Baxter) Bayer CSL Pfizer Biogen Octapharma NovoNordisk Geographically, this report studies the top producers
United States Recombinant Vaccine Market Report
In this report, the United States Recombinant Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share
Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Global Human Recombinant Insulin Market – Industry Insights
Discovery of insulin is considered to be one of the most important events in the history of the diabetes treatment. Furthermore, major advances in human insulin technology is the synthesis of human insulin analogue by recombinant technology. Currently, human insulin delivery system available for the administration of insulin include insulin syringes, insulin pumps, jet injections, and pens. Key players are focused on developing recombinant human insulin instead of animal-based insulin,
Global Human Recombinant Insulin Market – Industry Insights
Various government and private research organizations are engaged research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, American Diabetes Association (ADA) invested US$ 807.4 million in more than 4,700 research projects in diabetes research since 1952
Recombinant Vaccines Market Industry Forecast till 2025
Recombinant vaccines are produced by using recombinant DNA technology or genetic engineering for the prevention of lethal diseases in human beings and animals. Recombinant vaccine is a biological preparation that provides active acquired immunity against a certain disease. Whereas individual being vaccinated produces antibodies against the protein antigen that protect a person from contracting the disease upon attack from the pathogenic microorganism. These vaccines functions on the immune response for